Theravance Biopharma, Inc. (NASDAQ:TBPH) Stake Lessened by Baupost Group LLC MA

Baupost Group LLC MA decreased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 36.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,200,021 shares of the biopharmaceutical company’s stock after selling 2,394,105 shares during the period. Theravance Biopharma accounts for about 1.0% of Baupost Group LLC MA’s investment portfolio, making the stock its 20th largest holding. Baupost Group LLC MA owned 8.59% of Theravance Biopharma worth $35,616,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Theravance Biopharma in the second quarter worth about $129,000. Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma in the 2nd quarter worth approximately $108,000. Dimensional Fund Advisors LP lifted its stake in Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 91,679 shares during the last quarter. American Century Companies Inc. boosted its holdings in Theravance Biopharma by 11.7% during the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 6,026 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Theravance Biopharma in the second quarter worth approximately $286,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Eli Samaha acquired 999,800 shares of the stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares in the company, valued at approximately $74,186,970. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Stock Down 2.4 %

Theravance Biopharma stock opened at $8.01 on Friday. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $11.71. The company’s fifty day simple moving average is $8.70 and its 200-day simple moving average is $8.86. The stock has a market cap of $391.85 million, a P/E ratio of -9.31 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same period last year, the business earned ($0.28) earnings per share. On average, equities research analysts expect that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TBPH shares. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Finally, TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.